Jefferies Group’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Jefferies Group’s Portfolio ITCI Stock Details ITCI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-4,600	Closed	-$118	–	1591
2020 Q2	$118	Sell	4,600 -12,300	-73%	-$249K	﹤0.01%	1111
2020 Q1	$260K	Sell	16,900 -4,819,800	-100%	-$105M	﹤0.01%	1576
2019 Q4	$166M	Buy	4,836,700 +4,725,500	+4,250%	+$56.7M	1.28%	7
2019 Q3	$831K	Buy	111,200 +103,700	+1,383%	+$994K	0.01%	1614
2019 Q2	$97K	Buy	+7,500	New	+$96.2K	﹤0.01%	2288
2017 Q4	–	Sell	-178,700	Closed	-$2.82M	–	2876
2017 Q3	$2.82M	Buy	+178,700	New	+$2.62M	0.02%	772

Other funds holding ITCI

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Jefferies Group's ITCI Position: Q3 2022 in Review

Jefferies Group opened a new position in Intra-Cellular Therapies Inc. (ITCI) in Q3 2022: 6,365 shares worth $296K. The stake represents ﹤0.01% of the portfolio and ranks #1234 among its holdings. This is a return to the name: Jefferies Group previously reported a position in ITCI as recently as Q1 2020.

Jefferies Group first reported a position in ITCI in Q3 2017 and has held it in 6 quarters since. The position peaked at $2.82M in Q4 2019. 274 funds tracked by Wall St. Rank hold ITCI as of Q3 2022.

Jefferies Group held 6,365 shares of Intra-Cellular Therapies Inc. worth $296K as of Q3 2022.
Intra-Cellular Therapies Inc. was a new Jefferies Group position in Q3 2022.
Intra-Cellular Therapies Inc. made up ﹤0.01% of Jefferies Group's portfolio in Q3 2022, its #1234 holding.
Jefferies Group first reported a position in Intra-Cellular Therapies Inc. in Q3 2017 and has held it in 6 quarters since.
Jefferies Group's Intra-Cellular Therapies Inc. position peaked at $2.82M in Q4 2019.
274 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q3 2022.

Based on Jefferies Group's 13F filing for Q3 2022, filed 14 Nov 2022.